The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
about
Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsSignificance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinomaChronic hepatitis C: This and the new era of treatmentHepatitis C genotype 4: The past, present, and futureThe Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-AnalysisThe New Era of Interferon-Free Treatment of Chronic Hepatitis CInjecting drug use: A vector for the introduction of new hepatitis C virus genotypesValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceHepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in EuropeSASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infectionHepatitis C in Egypt - past, present, and futureModeling the Health and Economic Burden of Hepatitis C Virus in SwitzerlandHepatitis C virus infection.Global epidemiology and burden of HCV infection and HCV-related disease.Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypesReal-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening.Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up.Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014Hepatitis C infection in Egypt: prevalence, impact and management strategies.Hepatitis C Virus and Liver Transplantation.Limited access to hepatitis B/C treatment among vulnerable risk populations: an expert survey in six European countries.Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study.Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.Serum interferon-related microRNAs as biomarkers to predict the response to interferon therapy in chronic hepatitis C genotype 4Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionalsProjections of the current and future disease burden of hepatitis C virus infection in MalaysiaTreatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approachHepatitis C virus-induced hepatocellular carcinomaAre Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations.Temporal Changes in Post-Infectious Glomerulonephritis in Japan (1976-2009).A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care.Galactosylated Lipidoid Nanoparticles for Delivery of Small Interfering RNA to Inhibit Hepatitis C Viral Replication In Vivo.Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver diseaseA population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada
P2860
Q26747561-C9C3F2DA-035A-4CA4-A637-09D0CB9A668FQ26773251-5C12770D-9E6C-4A0A-AE57-006225399FDBQ26775011-88CA802B-B412-4E46-9371-4581BD4488ACQ26775815-D3E5609E-1191-40B8-BD55-1B9A577BB9C7Q26777560-5B342EC7-D317-4913-B9BB-20C6BD082440Q26777716-DD162B02-EEBC-4021-A80E-3E017544AA46Q26781991-327042C1-0AE0-45AE-92B1-4ABFAF1D883CQ28072257-17411AC8-CF57-4645-823C-A57EF085EAABQ28079580-AD3FBC49-1BAC-433B-8475-378247E0BB7EQ28082474-ED5F18E5-6B4B-4BE3-B02F-5AA4A9B8250BQ28354329-0F103310-B2B2-470A-8C1F-193CC6DD1B7DQ28548657-87FF1C7F-E135-43B6-97B9-1A99C6977308Q30235491-1BB14CD1-9922-4D07-A3FF-D1B1097EDFF9Q30240220-CC77E961-03E0-443B-B08B-D1B130552935Q30244767-2051B1BA-F82A-4717-B1FD-E7936FD8D7F7Q30245058-AA7E5F92-B4E1-4646-9AF7-A0F0E15D52B1Q33430833-12665460-0B5C-41AC-AA4A-8C9B377CAC51Q33563427-268F0833-183A-4085-9387-353543691D6AQ33578932-296D3E49-71D5-4310-81F1-5B05E05C312BQ33601691-91970C96-A4A1-4AE2-954E-D0A95DF9428BQ33713718-1689651C-CFBB-4954-B9AF-CA72BE8734F3Q33717116-49680C1D-49A8-4E71-AC3C-87B202C66A90Q33726797-ABFD762E-E618-4DCF-9AC5-877F1C5BAA42Q33876458-71756B12-95E1-4542-A647-6F0C5B5911C3Q34028307-D5BEB55A-E2C7-4CB0-B4AC-F7545B3D139BQ35196062-28A1CED5-352E-487B-A1D7-50CD777E5876Q35213230-D0240483-304F-4FD0-8B3C-4FB82D3B701DQ35652464-EB71EDFE-A10E-4BC6-ABEE-AFD060E51087Q35658214-A109C150-7435-4D0D-9F0E-8CD317A99E7EQ35724374-2B16B6F3-690D-4FC2-ADC9-FE58BD29DC82Q35824057-89D1E90E-3981-4A51-B0AB-7B785E659546Q35860136-D311A0C6-81B9-46D0-BB37-DD12BAD73C48Q35944276-AE1736B8-C5B9-419B-81E7-E53B46125EA9Q36029995-E0CB3BE9-B538-4C9B-AA7B-BBDE82F00A90Q36048445-AD4EC1B5-261B-42AA-833C-5198F1FE6464Q36161813-A66E3B44-AD65-4C48-BDC3-1105D40FE10DQ36172753-A7CE350A-84DC-4A4B-90E3-0648228B2F4DQ36192804-5442E90D-4C97-4E21-BF88-359752685BA7Q36243096-140C5C2C-26B9-4129-A7DF-C9A21575521CQ36279118-81EE367B-6799-4AE8-9C84-96B89EE77EF2
P2860
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The present and future disease ...... th today's treatment paradigm.
@en
The present and future disease burden of hepatitis C virus
@nl
type
label
The present and future disease ...... th today's treatment paradigm.
@en
The present and future disease burden of hepatitis C virus
@nl
prefLabel
The present and future disease ...... th today's treatment paradigm.
@en
The present and future disease burden of hepatitis C virus
@nl
P2093
P2860
P50
P356
P1476
The present and future disease ...... th today's treatment paradigm.
@en
P2093
A J Blasco
A J Thompson
A S Duberg
C E Brandão Mello
C Sarrazin
P2860
P356
10.1111/JVH.12248
P478
21 Suppl 1
P50
P577
2014-05-01T00:00:00Z